Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gritstone Bio Inc (GRTS)

Gritstone Bio Inc (GRTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,841
  • Shares Outstanding, K 108,569
  • Annual Sales, $ 16,340 K
  • Annual Income, $ -138,490 K
  • 60-Month Beta 0.50
  • Price/Sales 4.36
  • Price/Cash Flow N/A
  • Price/Book 5.04
Trade GRTS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.24
  • Most Recent Earnings $-0.34 on 05/09/24
  • Next Earnings Date 08/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 157.40% ( -46.72%)
  • Historical Volatility 74.13%
  • IV Percentile 43%
  • IV Rank 36.07%
  • IV High 387.94% on 07/03/24
  • IV Low 27.35% on 06/04/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 151
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 18,746
  • Open Int (30-Day) 18,450

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.25
  • Number of Estimates 4
  • High Estimate -0.18
  • Low Estimate -0.28
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +19.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5200 +25.48%
on 07/02/24
0.7295 -10.56%
on 06/27/24
-0.0475 (-6.79%)
since 06/26/24
3-Month
0.5200 +25.48%
on 07/02/24
1.0400 -37.26%
on 05/07/24
-0.1609 (-19.78%)
since 04/26/24
52-Week
0.5200 +25.48%
on 07/02/24
3.3300 -80.41%
on 10/10/23
-1.2975 (-66.54%)
since 07/26/23

Most Recent Stories

More News
Stocks Tread Water Before the Open as Investors Await Key U.S. GDP Data, Nike Earnings on Tap

December S&P 500 futures (ESZ23) are up +0.04%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.05% this morning as market participants geared up for a flurry of U.S. economic data while also...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
NEE : 74.26 (+1.12%)
ZION : 52.29 (+0.95%)
PAYX : 125.75 (+1.43%)
NKE : 72.56 (+1.61%)
ACN : 328.46 (-0.50%)
JBL : 110.38 (+0.03%)
KMX : 83.02 (+1.80%)
RYA.I.DX : 15.000 (+4.13%)
MU : 109.41 (+1.82%)
PTON : 3.60 (+4.35%)
Gritstone Appoints Dr. Lawrence “Larry” Corey to its Board of Directors

-- Expert in virology, immunology and vaccine development’s appointment effective August 12 --...

GRTS : 0.6525 (-0.65%)
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...

GRTS : 0.6525 (-0.65%)
Gritstone to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 4, 2022

Conference call to occur at 4:30pm ET on August 4...

GRTS : 0.6525 (-0.65%)
Gritstone Announces Results from Preclinical Study of its Self-amplifying mRNA (samRNA) Vaccine Against SARS-CoV-2 Published in Nature Communications

-- Results, which were previously pre-printed in bioRxiv, show Gritstone’s second-generation self-amplifying mRNA (samRNA) vaccine candidate drove broad...

GRTS : 0.6525 (-0.65%)
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...

GRTS : 0.6525 (-0.65%)
Gritstone Earns 2022 Great Place to Work Certification™

EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...

GRTS : 0.6525 (-0.65%)
Gritstone to Participate in H.C. Wainwright Global Investment Conference

EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the...

GRTS : 0.6525 (-0.65%)
CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update

-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data...

GRTS : 0.6525 (-0.65%)
Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next...

GRTS : 0.6525 (-0.65%)

Business Summary

Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict...

See More

Key Turning Points

3rd Resistance Point 0.7133
2nd Resistance Point 0.6930
1st Resistance Point 0.6727
Last Price 0.6525
1st Support Level 0.6321
2nd Support Level 0.6118
3rd Support Level 0.5915

See More

52-Week High 3.3300
Fibonacci 61.8% 2.2566
Fibonacci 50% 1.9250
Fibonacci 38.2% 1.5934
Last Price 0.6525
52-Week Low 0.5200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar